U.S. well being officers’ approval course of for Biogen Inc.’s controversial Alzheimer’s drug was “rife with irregularities,” elevating critical considerations about protocol lapses on the company, congressional investigators mentioned.
The Meals and Drug Administration collaborated excessively with Biogen whereas assessing the drug, referred to as Aduhelm, in response to the report on an 18-month investigation revealed Thursday by two Home committees, Oversight and Reform and Vitality and…
